Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients.
Hepatitis is a frequent complication of dialysis and renal transplantation; therefore, the occurrence of drug hepatotoxicity is an additional important consideration in renal allograft recipients. Azathioprine, needed for immunosuppression, and isoniazid, used for antituberculous chemoprophylaxis, are both potentially hepatotoxic. A retrospective study of 119 patients who received 126 renal allografts was done to estimate the probable incidence of isoniazid-related hepatic dysfunction. All patients in this series were administered isoniazid chemoprophylaxis. Posttransplantation hepatitis developed in 13 patients. Circumstantial evidence supported a presumptive diagnosis of isoniazid hepatotoxicity in three recipients. We concluded that routine isoniazid chemoprophylaxis is not justified in renal allograft recipients based on the probability of hepatotoxicity as contrasted to the infrequent occurrence of tuberculosis.
D000293:Adolescent; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002648:Child; D006514:Hepatitis B Surface Antigens; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008099:Liver / Q000187:drug effects*; D008875:Middle Aged; D011183:Postoperative Complications; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*
D006514:Hepatitis B Surface Antigens; D007538:Isoniazid